{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087014","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.214511+00:00","generated_at":"2026-05-31T10:49:37.933593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Carisma Therapeutics Q2 2024 net loss $11.2M; CT-0525 data expected by year-end","bullets":["Net loss improved to $11.2M in Q2 2024 from $19.9M in Q2 2023; R&D expenses declined to $15.3M.","Cash and equivalents $40.4M at June 30, 2024; expects to fund operations into Q3 2025.","Initial data from CT-0525 Phase 1 trial for HER2+ solid tumors expected by year-end 2024; FDA Fast Track granted.","Nominated first in vivo CAR-M development candidate targeting GPC3 under Moderna collaboration; $2.0M milestone received.","Liver fibrosis program development candidate nomination expected in Q1 2025; preclinical data at AASLD in Nov 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087014","json":"https://secwatch.observer/filing/0001104659-24-087014.json","markdown":"https://secwatch.observer/filing/0001104659-24-087014.md","text":"https://secwatch.observer/filing/0001104659-24-087014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924087014/0001104659-24-087014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924087014/tm2420899d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:49:37.933593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}